CellCarta Naperville Lab | Genomic and Histopathology Services

October 12, 2022

Step Into Our Naperville Facility!

In 2022, we proudly announced the grand opening of our Naperville, Chicago location!

Our new facility is only 30 minutes from the Chicago O’Hare airport and encompasses over 3,000m2 (29,283 sq ft) of innovative scientific equipment and highly trained staff.

As part of CellCarta’s global CRO infrastructure, this lab strengthens our clinical trial support capabilities across North America.

Join us for a tour and see how CellCarta is dedicated to advancing scientific research.

At Naperville, we offer testing services for all phases of clinical trials. As a CRO with multiomics capabilities, we support:

Genomics

Our Naperville facility is designed to provide comprehensive testing services across various phases of clinical trials. Our advanced genomic capabilities include-

  • RT-PCR

These techniques are essential for precise genetic analysis and biomarker discovery, aiding in the development of targeted therapies and personalized medicine.

We support both preclinical and clinical studies across oncology and immunology, as well as specialized therapeutic development such as ADC programs.

Histopathology

In addition to our robust genomic services, we offer state-of-the-art histopathology services.

  • Software platforms include: Indica Labs’ HALO®, Visiopharm®,  Akoya’s inForm®, CyteHub®, SoloWeb, and navify® by Roche.

As a CAP/CLIA certified lab, we support clinical studies for diagnostic and pharmaceutical partners in preparation for FDA, EU and other global submissions.

Our histology CRO services are integrated into our multiomic CRO offerings, enabling scalable analysis pipelines for high-volume biomarker testing across platforms and therapeutic areas.

We support both preclinical and clinical studies across oncology, immunology, and more, with specialized support for ADC development programs.

Commitment to Quality and Compliance

As a CAP accredited and CLIA certified laboratory, we adhere to the highest standards of quality and compliance.

Our rigorous quality control measures ensure the reliability and accuracy of our data, supporting clinical studies for regulatory submissions worldwide, including FDA and EU approvals.

Our quality management system (QMS) drives harmonization of specific testing services and related activities and is implemented at all levels of the organization.

Strategic Location and Accessibility

Located just 30 minutes from Chicago O’Hare airport, our Naperville facility is easily accessible for local and international clients. The facility spans over 3,000m² (29,283 sq ft) and is equipped with the latest scientific equipment, operated by a team of highly trained professionals dedicated to advancing scientific research.

Why Choose CellCarta?

CellCarta is committed to delivering high-quality, reliable data through our extensive range of testing services and advanced technologies. Our new Naperville facility exemplifies our dedication to supporting clinical trials and research initiatives with state-of-the-art resources and expert staff.

As a global CRO, our Naperville site provides key clinical trial services in genomics, histopathology, and biomarker programs.

Backed by our expert scientific teams and cutting-edge platforms, we help biopharma clients accelerate drug development with data they can trust.

CellCarta Naperville Lab | Genomic and Histopathology Services

October 12, 2022

Step Into Our Naperville Facility!

In 2022, we proudly announced the grand opening of our Naperville, Chicago location!

Our new facility is only 30 minutes from the Chicago O’Hare airport and encompasses over 3,000m2 (29,283 sq ft) of innovative scientific equipment and highly trained staff.

As part of CellCarta’s global CRO infrastructure, this lab strengthens our clinical trial support capabilities across North America.

Join us for a tour and see how CellCarta is dedicated to advancing scientific research.

At Naperville, we offer testing services for all phases of clinical trials. As a CRO with multiomics capabilities, we support:

Genomics

Our Naperville facility is designed to provide comprehensive testing services across various phases of clinical trials. Our advanced genomic capabilities include-

  • RT-PCR

These techniques are essential for precise genetic analysis and biomarker discovery, aiding in the development of targeted therapies and personalized medicine.

We support both preclinical and clinical studies across oncology and immunology, as well as specialized therapeutic development such as ADC programs.

Histopathology

In addition to our robust genomic services, we offer state-of-the-art histopathology services.

  • Software platforms include: Indica Labs’ HALO®, Visiopharm®,  Akoya’s inForm®, CyteHub®, SoloWeb, and navify® by Roche.

As a CAP/CLIA certified lab, we support clinical studies for diagnostic and pharmaceutical partners in preparation for FDA, EU and other global submissions.

Our histology CRO services are integrated into our multiomic CRO offerings, enabling scalable analysis pipelines for high-volume biomarker testing across platforms and therapeutic areas.

We support both preclinical and clinical studies across oncology, immunology, and more, with specialized support for ADC development programs.

Commitment to Quality and Compliance

As a CAP accredited and CLIA certified laboratory, we adhere to the highest standards of quality and compliance.

Our rigorous quality control measures ensure the reliability and accuracy of our data, supporting clinical studies for regulatory submissions worldwide, including FDA and EU approvals.

Our quality management system (QMS) drives harmonization of specific testing services and related activities and is implemented at all levels of the organization.

Strategic Location and Accessibility

Located just 30 minutes from Chicago O’Hare airport, our Naperville facility is easily accessible for local and international clients. The facility spans over 3,000m² (29,283 sq ft) and is equipped with the latest scientific equipment, operated by a team of highly trained professionals dedicated to advancing scientific research.

Why Choose CellCarta?

CellCarta is committed to delivering high-quality, reliable data through our extensive range of testing services and advanced technologies. Our new Naperville facility exemplifies our dedication to supporting clinical trials and research initiatives with state-of-the-art resources and expert staff.

As a global CRO, our Naperville site provides key clinical trial services in genomics, histopathology, and biomarker programs.

Backed by our expert scientific teams and cutting-edge platforms, we help biopharma clients accelerate drug development with data they can trust.

Digital PCR Applications: Advancing Clinical Research

June 1, 2022

In this webinar, Dr. Jan Hellemans describes the intrinsic potential of droplet digital PCR (ddPCR) in clinical research for three different applications:

  • rare variant analysis in plasma samples,
  • small changes in alternative splicing, and
  • CAR-T studies.

Since becoming commercially available in 2011, digital PCR (dPCR) has been gaining in popularity as it enables nucleic acid quantification with superior accuracy and precision compared to quantitative PCR (qPCR). In brief, the technology consists of the following steps:

  1. The PCR reaction mixture is partitioned into thousands of water-in-oil droplets with target and background DNA randomly distributed among the reactions.
  2. The target DNA is amplified by PCR using standard thermal cycling with fluorescent dyes or probes.
  3. Each reaction provides a fluorescent positive or negative signal indicating that target DNA was present or absent in partitioning.
  4. The fraction of positive droplets is used to calculate the target DNA concentration using Poisson correction.

With data acquisition taking place at the end of the reaction, and since absolute concentrations can be determined, data can be easily interpreted and compared across different samples and experiments, especially in a clinical setting.

Additionally, dPCR doesn’t suffer from the inherent complications of qPCR that result from the requirement of a standard curve and excels in the quantification of low abundant genes or small differences.

Learn more about digital PCR.

Digital PCR Applications: Advancing Clinical Research

June 1, 2022

In this webinar, Dr. Jan Hellemans describes the intrinsic potential of droplet digital PCR (ddPCR) in clinical research for three different applications:

  • rare variant analysis in plasma samples,
  • small changes in alternative splicing, and
  • CAR-T studies.

Since becoming commercially available in 2011, digital PCR (dPCR) has been gaining in popularity as it enables nucleic acid quantification with superior accuracy and precision compared to quantitative PCR (qPCR). In brief, the technology consists of the following steps:

  1. The PCR reaction mixture is partitioned into thousands of water-in-oil droplets with target and background DNA randomly distributed among the reactions.
  2. The target DNA is amplified by PCR using standard thermal cycling with fluorescent dyes or probes.
  3. Each reaction provides a fluorescent positive or negative signal indicating that target DNA was present or absent in partitioning.
  4. The fraction of positive droplets is used to calculate the target DNA concentration using Poisson correction.

With data acquisition taking place at the end of the reaction, and since absolute concentrations can be determined, data can be easily interpreted and compared across different samples and experiments, especially in a clinical setting.

Additionally, dPCR doesn’t suffer from the inherent complications of qPCR that result from the requirement of a standard curve and excels in the quantification of low abundant genes or small differences.

Learn more about digital PCR.